Biomarkers such as baseline HbA1c, fasting glucose, leptin, GLP-1 baseline levels, and inflammatory markers (CRP, IL-6) may provide context for treatment suitability
Therefore, it is crucial to increase the bioavailability of BBR by different means
Patients were sorted into 2 cohorts based on whether they had received a prescription for a GLP-1 RA (semaglutide, lixisenatide, tirzepatide, dulaglutide, liraglutide, or exenatide): those with GLP-1 RA prescriptions were considered the treatment group, whereas those without GLP-1 RA prescriptions were considered the control group
Nitric oxide synthase inhibition prevents activity-induced calcineurin-NFATc1 signalling and fast- to-slow skeletal muscle fibre type conversions